FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100807510> ?p ?o ?g. }

• W3100807510 abstract "Background Immune checkpoint inhibitors (ICIs) have increased in prevalence for the treatment of metastatic clear-cell renal cell carcinoma (mccRCC) in recent years given their efficacy and favorable toxicity profile. However, there has been insufficient investigation in the literature of how clinical outcomes differ on the basis of race. In this paper, we investigated differences in clinical outcomes between African American (AA) and Caucasian mRCC patients treated with ICI therapy. Methods We performed a retrospective study of 198 patients with mRCC who received ICI at the Emory Winship Cancer Institute from 2015–2020. Clinical outcomes were measured by overall survival (OS), progression-free survival (PFS), and clinical benefit (CB). OS and PFS were calculated from ICI-initiation to date of death and radiographic or clinical progression, respectively. CB was defined as a best radiographic response of complete response, partial response, or stable disease maintained for at least 6 months per response evaluation criteria in solid tumors version 1.1. The association of self-identified race with OS and PFS was generally modeled by Cox proportional hazards model. Univariable and multivariable logistic regression models were used for binary outcomes of CB. The univariate association of immune-related adverse events (irAEs) and non-clear-cell RCC (nccRCC) with race was assessed using Chi-square test. Results Our cohort was made up of 38 AA (19%) and 160 Caucasian (81%) patients. Most of the patients were diagnosed with ccRCC (78%) and more than half received PD-1 monotherapy (57%). Most patients were international mRCC database consortium (IMDC) intermediate (57%) or poor-risk (25%) groups. AA patients displayed significantly shorter PFS (HR=1.52, 95% CI: 1.01–2.3, p=0.045) and trended towards decreased CB (OR=0.51, 95% CI: 0.22–1.17, p=0.111) in MVA (table 1). There was no difference in OS (HR=1.09, 95% CI: 0.61–1.95, p=0.778) between the two racial groups in MVA (table 1). On Kaplan-Meier method, AA patients had shorter median OS (17 vs 25 months, p=0.3676) and median PFS (3.1 vs 4.4 months, p=0.0676) relative to Caucasian patients (figure 1). Additionally, AA patients more commonly had nccRCC compared to Caucasian patients (41.7% vs 17.5% nccRCC, p-0.002). AA patients also trended towards a lower incidence of irAEs compared to Caucasian patients in UVA (23.7% vs 35.8%, p=0.153). Abstract 223 Table 1 *MVA controlled for age, race, gender, IMDC risk group, number of prior lines of therapy, PD-1 monotherapy, and ccRCC**statistical significance at alpha < 0.05 Abstract 223 Figure 1 African-American (black) and Caucasian (white) for OS (left panel) and PFS (right panel) Conclusions In this group of mRCC patients treated with ICI, African American patients had significantly shorter PFS compared to Caucasian patients. These findings suggest race could play a role in the management of late-stage mRCC. Larger, prospective studies are needed to validate these findings. Acknowledgements Research reported in this publication was supported in part by the Breen Foundation and the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Trial Registration Not applicable. Ethics Approval This retrospective study was approved by the Emory University Institutional Review Board. Consent Not applicable. References Not applicable" @default.
• W3100807510 created "2020-11-23" @default.
• W3100807510 creator A5010114692 @default.
• W3100807510 creator A5013832255 @default.
• W3100807510 creator A5029487343 @default.
• W3100807510 creator A5030315601 @default.
• W3100807510 creator A5035665916 @default.
• W3100807510 creator A5036847798 @default.
• W3100807510 creator A5042777250 @default.
• W3100807510 creator A5046214153 @default.
• W3100807510 creator A5049071296 @default.
• W3100807510 creator A5049461163 @default.
• W3100807510 creator A5050579893 @default.
• W3100807510 creator A5058303985 @default.
• W3100807510 creator A5061066145 @default.
• W3100807510 creator A5075438799 @default.
• W3100807510 creator A5086546163 @default.
• W3100807510 creator A5089787590 @default.
• W3100807510 creator A5090286284 @default.
• W3100807510 date "2020-11-01" @default.
• W3100807510 modified "2023-10-17" @default.
• W3100807510 title "223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy" @default.
• W3100807510 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0223" @default.
• W3100807510 hasPublicationYear "2020" @default.
• W3100807510 type Work @default.
• W3100807510 sameAs 3100807510 @default.
• W3100807510 citedByCount "0" @default.
• W3100807510 crossrefType "journal-article" @default.
• W3100807510 hasAuthorship W3100807510A5010114692 @default.
• W3100807510 hasAuthorship W3100807510A5013832255 @default.
• W3100807510 hasAuthorship W3100807510A5029487343 @default.
• W3100807510 hasAuthorship W3100807510A5030315601 @default.
• W3100807510 hasAuthorship W3100807510A5035665916 @default.
• W3100807510 hasAuthorship W3100807510A5036847798 @default.
• W3100807510 hasAuthorship W3100807510A5042777250 @default.
• W3100807510 hasAuthorship W3100807510A5046214153 @default.
• W3100807510 hasAuthorship W3100807510A5049071296 @default.
• W3100807510 hasAuthorship W3100807510A5049461163 @default.
• W3100807510 hasAuthorship W3100807510A5050579893 @default.
• W3100807510 hasAuthorship W3100807510A5058303985 @default.
• W3100807510 hasAuthorship W3100807510A5061066145 @default.
• W3100807510 hasAuthorship W3100807510A5075438799 @default.
• W3100807510 hasAuthorship W3100807510A5086546163 @default.
• W3100807510 hasAuthorship W3100807510A5089787590 @default.
• W3100807510 hasAuthorship W3100807510A5090286284 @default.
• W3100807510 hasConcept C121608353 @default.
• W3100807510 hasConcept C126322002 @default.
• W3100807510 hasConcept C143998085 @default.
• W3100807510 hasConcept C144301174 @default.
• W3100807510 hasConcept C167135981 @default.
• W3100807510 hasConcept C2776694085 @default.
• W3100807510 hasConcept C2777472916 @default.
• W3100807510 hasConcept C2780739268 @default.
• W3100807510 hasConcept C2781278892 @default.
• W3100807510 hasConcept C38180746 @default.
• W3100807510 hasConcept C50382708 @default.
• W3100807510 hasConcept C71924100 @default.
• W3100807510 hasConcept C72563966 @default.
• W3100807510 hasConceptScore W3100807510C121608353 @default.
• W3100807510 hasConceptScore W3100807510C126322002 @default.
• W3100807510 hasConceptScore W3100807510C143998085 @default.
• W3100807510 hasConceptScore W3100807510C144301174 @default.
• W3100807510 hasConceptScore W3100807510C167135981 @default.
• W3100807510 hasConceptScore W3100807510C2776694085 @default.
• W3100807510 hasConceptScore W3100807510C2777472916 @default.
• W3100807510 hasConceptScore W3100807510C2780739268 @default.
• W3100807510 hasConceptScore W3100807510C2781278892 @default.
• W3100807510 hasConceptScore W3100807510C38180746 @default.
• W3100807510 hasConceptScore W3100807510C50382708 @default.
• W3100807510 hasConceptScore W3100807510C71924100 @default.
• W3100807510 hasConceptScore W3100807510C72563966 @default.
• W3100807510 hasLocation W31008075101 @default.
• W3100807510 hasOpenAccess W3100807510 @default.
• W3100807510 hasPrimaryLocation W31008075101 @default.
• W3100807510 hasRelatedWork W10356367 @default.
• W3100807510 hasRelatedWork W12581806 @default.
• W3100807510 hasRelatedWork W13362822 @default.
• W3100807510 hasRelatedWork W13397619 @default.
• W3100807510 hasRelatedWork W13505963 @default.
• W3100807510 hasRelatedWork W14127037 @default.
• W3100807510 hasRelatedWork W18431496 @default.
• W3100807510 hasRelatedWork W19124980 @default.
• W3100807510 hasRelatedWork W7720014 @default.
• W3100807510 hasRelatedWork W8076426 @default.
• W3100807510 isParatext "false" @default.
• W3100807510 isRetracted "false" @default.
• W3100807510 magId "3100807510" @default.
• W3100807510 workType "article" @default.